Review of the Psoriatic Arthritis Working Group at OMERACT 12: A Report from the GRAPPA 2014 Annual Meeting

At the 2014 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), the psoriatic arthritis (PsA) working group of OMERACT (Outcome Measures in Rheumatology) presented a review of the progress made at the OMERACT 12 meeting, held in 2014. Members of the PsA OMERACT working group presented work from the Patient Involvement in Outcome Measures for PsA initiative to improve the incorporation of patient research partners in PsA outcomes research, the results of discussions within the OMERACT breakout groups, and finally the voting results. The OMERACT 12 participants had endorsed the need to update the PsA core set according to the Filter 2.0 framework. The breakout group discussions identified potential opportunities for revising the core set, including consolidating existing redundancy within the core set, improving incorporation of the patient perspective, and including disease effects such as fatigue as a core criterion. GRAPPA members of the OMERACT working group now have a program of research to update the core set with the goal of seeking endorsement at OMERACT 13, to be held in 2016.

Download Full-text

Enhanced Patient Involvement and the Need to Revise the Core Set — Report from the Psoriatic Arthritis Working Group at OMERACT 2014

The Journal of Rheumatology ◽

10.3899/jrheum.141156 ◽

2015 ◽

Vol 42 (11) ◽

pp. 2198-2203 ◽

Cited By ~ 24

Author(s):

William Tillett ◽

Lihi Eder ◽

Niti Goel ◽

Maarten De Wit ◽

Dafna D. Gladman ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Working Group ◽

Patient Involvement ◽

Composite Index ◽

Research Review ◽

The Core ◽

Core Set ◽

New Research ◽

Longitudinal Observational Studies ◽

Future Work

Objective.To discuss the need for revision of the “core set” of domains to be included for assessment in psoriatic arthritis (PsA) randomized controlled trials and longitudinal observational studies, review work undertaken since the 2012 meeting of Outcome Measures for Rheumatology 11 (OMERACT 11) to include patient perspectives in this revision, and reassess proposed composite measures in the context of new research data and the OMERACT Filter 2.0 framework.Methods.The OMERACT 12 (2014) PsA working group presented work completed over the last 2 years to incorporate patient involvement in PsA outcomes research, review the endorsed PsA core set based on the patient perspective as well as new research findings, and further develop PsA responder indices. Breakout groups then discussed 2 topics: (1) the need to revise the PsA core set, and opportunities to add, move, or merge existing domains to improve existing redundancy; and (2) how to incorporate the core set in a composite index. Breakout groups fed back to the working group before participant voting.Results.Meeting participants endorsed the need to revise the PsA core set according to the OMERACT Filter 2.0 framework (100%), and the inclusion of disease impact (94%) and fatigue (72%) in the inner circle. Breakout group feedback suggested the core set revision was an opportunity to consolidate pathophysiologic aspects such as arthritis, enthesitis, dactylitis, spondylitis as “inflammatory musculoskeletal disease,” and nail and skin psoriasis as “psoriasis activity.”Conclusion.Future work will focus on updating the PsA core set and development of responder indices with ongoing, meaningful involvement of patient research partners.

Download Full-text

Arthritis Mutilans: A Report from the GRAPPA 2012 Annual Meeting

The Journal of Rheumatology ◽

10.3899/jrheum.130453 ◽

2013 ◽

Vol 40 (8) ◽

pp. 1419-1422 ◽

Cited By ~ 8

Author(s):

Vinod Chandran ◽

Dafna D. Gladman ◽

Philip S. Helliwell ◽

Björn Gudbjörnsson

Keyword(s):

Psoriatic Arthritis ◽

Annual Meeting ◽

Clinical Features ◽

Severe Form ◽

Group Discussions ◽

Epidemiological Research ◽

Breakout Group ◽

Definition Of ◽

Arthritis Mutilans ◽

Broad Consensus

Arthritis mutilans is often described as the most severe form of psoriatic arthritis. However, a widely agreed on definition of the disease has not been developed. At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members hoped to agree on a definition of arthritis mutilans and thus facilitate clinical and molecular epidemiological research into the disease. Members discussed the clinical features of arthritis mutilans and definitions used by researchers to date; reviewed data from the ClASsification for Psoriatic ARthritis study, the Nordic psoriatic arthritis mutilans study, and the results of a premeeting survey; and participated in breakout group discussions. Through this exercise, GRAPPA members developed a broad consensus on the features of arthritis mutilans, which will help us develop a GRAPPA-endorsed definition of arthritis mutilans.

Download Full-text

The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set

The Journal of Rheumatology ◽

10.3899/jrheum.190122 ◽

2019 ◽

Vol 95 ◽

pp. 33-37

Author(s):

Ying Ying Leung ◽

Ana-Maria Orbai ◽

Alexis Ogdie ◽

Laura C. Coates ◽

Maarten de Wit ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Annual Meeting ◽

Working Group ◽

Outcome Measurement ◽

Meeting Report ◽

Core Outcome ◽

The Core

Download Full-text

Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016

The Journal of Rheumatology ◽

10.3899/jrheum.161389 ◽

2017 ◽

Vol 44 (12) ◽

pp. 1884-1888 ◽

Cited By ~ 3

Author(s):

Esi M. Morgan ◽

Meredith P. Riebschleger ◽

Jennifer Horonjeff ◽

Alessandro Consolaro ◽

Jane E. Munro ◽

...

Keyword(s):

Juvenile Idiopathic Arthritis ◽

Literature Review ◽

Outcome Measures ◽

Interest Group ◽

Special Interest ◽

Working Group ◽

Qualitative Studies ◽

Special Interest Group ◽

The Core ◽

Core Set

Objective.The current Juvenile Idiopathic Arthritis (JIA) Core Set was developed in 1997 to identify the outcome measures to be used in JIA clinical trials using statistical and consensus-based techniques, but without patient involvement. The importance of patient/parent input into the research process has increasingly been recognized over the years. An Outcome Measures in Rheumatology (OMERACT) JIA Core Set Working Group was formed to determine whether the outcome domains of the current core set are relevant to those involved or whether the core set domains should be revised.Methods.Twenty-four people from the United States, Canada, Australia, and Europe, including patient partners, formed the working group. Guided by the OMERACT Filter 2.0 process, we performed (1) a systematic literature review of outcome domains, (2) a Web-based survey (142 patients, 343 parents), (3) an idea-generation study (120 parents), (4) 4 online discussion boards (24 patients, 20 parents), and (5) a Special Interest Group (SIG) activity at the OMERACT 13 (2016) meeting.Results.A MEDLINE search of outcome domains used in studies of JIA yielded 5956 citations, of which 729 citations underwent full-text review, and identified additional domains to those included in the current JIA Core Set. Qualitative studies on the effect of JIA identified multiple additional domains, including pain and participation. Twenty-one participants in the SIG achieved consensus on the need to revise the entire JIA Core Set.Conclusion.The results of qualitative studies and literature review support the need to expand the JIA Core Set, considering, among other things, additional patient/parent-centered outcomes, clinical data, and imaging data.

Download Full-text

Report of the Skin Research Working Groups From the GRAPPA 2020 Annual Meeting

The Journal of Rheumatology ◽

10.3899/jrheum.201668 ◽

2021 ◽

pp. jrheum.201668

Author(s):

Lourdes M. Perez-Chada ◽

Alison Kohn ◽

Alice B. Gottlieb ◽

April W. Armstrong ◽

Lihi Eder ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Annual Meeting ◽

Outcome Measures ◽

Working Group ◽

Treatment Satisfaction ◽

Panel Discussion ◽

Musculoskeletal Symptoms ◽

Working Groups ◽

Feasible Outcome ◽

Longitudinal Observational Studies

At the 2020 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), the International Dermatology Outcome Measures (IDEOM) Initiative Psoriasis (PsO) Working Group presented an update on its work to agree on meaningful, valid, and feasible outcome measures for PsO randomized controlled trials and longitudinal observational studies. The Treatment Satisfaction Working Group presented the development of a treatment satisfaction instrument to be utilized in PsO clinical trials. The Musculoskeletal Symptoms Working Group presented an overview of their work conducted to date to define how to best measure musculoskeletal symptoms in PsO clinical studies, and discussed next steps during an open-panel discussion, which included PsO and psoriatic arthritis experts.

Download Full-text

The Need to Define Musculoskeletal Inflammation: A Report from the GRAPPA 2010 Annual Meeting

The Journal of Rheumatology ◽

10.3899/jrheum.111236 ◽

2012 ◽

Vol 39 (2) ◽

pp. 413-414 ◽

Cited By ~ 3

Author(s):

AMIT GARG ◽

DAFNA D. GLADMAN ◽

PHILIP J. MEASE

Keyword(s):

Psoriatic Arthritis ◽

Annual Meeting ◽

Inflammatory Arthritis ◽

Disease Classification ◽

Group Discussions ◽

Diagnostic Measure ◽

Breakout Group

Psoriatic arthritis (PsA) is a form of spondyloarthritis, a group of conditions that share a spectrum of components including arthritis, enthesitis, dactylitis, and spine inflammation. In PsA, however, the unpredictable, heterogeneous, and often insidious involvement of joints or juxtaarticular tendons and ligaments can sometimes make clinical recognition of the disease a challenge. Underrecognition of PsA may be due to the absence of a single sensitive and specific diagnostic measure. Although the ClASsification of Psoriatic ARthritis (CASPAR) criteria introduced in 2006 have improved disease classification, they are designed to be applied to cases already diagnosed with inflammatory arthritis. Therefore, in order for these criteria to be applied, the clinician is required to recognize the presence of inflammatory arthritis, enthesitis, or spondylitis. At the 2010 annual meeting of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), the need to define inflammatory arthritis, enthesitis, dactylitis, and spondylitis, especially for nonrheumatologists, was discussed. Conclusions from breakout group discussions are summarized.

Download Full-text

Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group

The Journal of Rheumatology ◽

10.3899/jrheum.170150 ◽

2017 ◽

Vol 44 (5) ◽

pp. 697-700 ◽

Cited By ~ 18

Author(s):

Alexis Ogdie ◽

Maarten de Wit ◽

Kristina Callis Duffin ◽

Willemina Campbell ◽

Jeffrey Chau ◽

...

Keyword(s):

Clinical Trials ◽

Psoriatic Arthritis ◽

Outcome Measures ◽

Working Group ◽

Development Process ◽

Outcome Measurement ◽

Core Outcome ◽

Core Domain ◽

Core Set ◽

Core Domain Set

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Core Set working group recently published the updated 2016 psoriatic arthritis (PsA) core domain set, a set of disease features that should be measured in all clinical trials. At the GRAPPA annual meeting in July 2016, the PsA working group presented the updated PsA core domain set endorsed by 90% of participants at OMERACT in May 2016 and drafted a roadmap for the development of the PsA core outcome measurement set. In this manuscript, we review the development process of the PsA core domain set and the ongoing and proposed work streams for development of a PsA core measurement set.

Download Full-text

On Defining Musculoskeletal Inflammation: A Report from the GRAPPA 2011 Annual Meeting

The Journal of Rheumatology ◽

10.3899/jrheum.120827 ◽

2012 ◽

Vol 39 (11) ◽

pp. 2214-2215 ◽

Cited By ~ 3

Author(s):

AMIT GARG ◽

DAFNA D. GLADMAN ◽

PHILIP J. MEASE

Keyword(s):

Psoriatic Arthritis ◽

Annual Meeting ◽

Inflammatory Arthritis ◽

Classification Criteria ◽

Musculoskeletal Disease ◽

Group Discussions ◽

Diagnostic Measure ◽

Breakout Group

At the 2011 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members discussed the need to develop a framework for defining inflammatory arthritis, enthesitis, dactylitis, and spondylitis, particularly as they relate to psoriatic arthritis (PsA). GRAPPA members first addressed this subject at their 2010 meeting, where the CASPAR (ClASsification of Psoriatic ARthritis) criteria were discussed. Although these are classification criteria, the CASPAR are also often applied as a diagnostic measure by clinicians screening for PsA, particularly its core criterion: recognizing the presence of inflammatory musculoskeletal disease. In breakout group discussions, GRAPPA members discussed the difficulties in recognizing overlapping or mimicking features that may result in underdiagnosing or misdiagnosing PsA.

Download Full-text

Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis

The Journal of Rheumatology ◽

10.3899/jrheum.191119 ◽

2020 ◽

Vol 48 (1) ◽

pp. 58-66 ◽

Cited By ~ 1

Author(s):

Ying Ying Leung ◽

Ana-Maria Orbai ◽

Alexis Ogdie ◽

Pil Hojgaard ◽

Richard Holland ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Physical Function ◽

Outcome Measures ◽

Physical Functioning ◽

Working Group ◽

Short Form ◽

Outcome Measurement ◽

Patient Reported Outcome Measures ◽

Measurement Information ◽

Patient Reported

Objective.Numerous patient-reported outcome measures (PROM) exist for the measurement of physical function for psoriatic arthritis (PsA), but only a few are validated comprehensively. The objective of this project was to prioritize PROM for measuring physical function for potential incorporation into a standardized outcome measurement set for PsA.Methods.A working group of 13 members including 2 patient research partners was formed. PROM measuring physical function in PsA were identified through a systematic literature review and recommendations by the working group. The rationale for inclusion and exclusion from the original list of existing PROM was thoroughly discussed and 2 rounds of Delphi exercises were conducted to achieve consensus.Results.Twelve PROM were reviewed and discussed. Six PROM were prioritized: Health Assessment Questionnaire (HAQ) and 4 modifications (HAQ-Disability Index, HAQ-Spondyloarthritis, modified HAQ, multidimensional HAQ), Medical Outcomes Study 36-item Short Form survey physical functioning domain, and the Patient-Reported Outcomes Measurement Information System (PROMIS) physical functioning module.Conclusion.Through discussion and Delphi exercises, we achieved consensus to prioritize 6 physical function PROM for PsA. These 6 PROM will undergo further appraisal using the Outcome Measures in Rheumatology (OMERACT) Filter 2.1.

Download Full-text

Developing a Core Set of Outcome Measures for Behçet Disease: Report from OMERACT 2016

The Journal of Rheumatology ◽

10.3899/jrheum.161352 ◽

2017 ◽

Vol 44 (11) ◽

pp. 1750-1753 ◽

Cited By ~ 14

Author(s):

Gulen Hatemi ◽

Alexa Meara ◽

Yesim Ozguler ◽

Haner Direskeneli ◽

Alfred Mahr ◽

...

Keyword(s):

Clinical Trials ◽

Outcome Measures ◽

Working Group ◽

Organ Involvement ◽

Future Research ◽

Behçet Disease ◽

Behcet Disease ◽

Core Set ◽

Patient Reported ◽

Specific Organ

Objective.The Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group has been working toward developing a data-driven core set of outcome measures for use in clinical trials of Behçet’s syndrome [Behçet disease (BD)]. This paper summarizes the group’s work through OMERACT 2016, discussions during the meeting, and the future research agenda.Methods.Qualitative patient interviews were conducted among 20 patients with BD who have different types of organ involvement. A 3-round Delphi among BD experts and patients was initiated to identify domains, subdomains, and outcomes to be assessed in clinical trials of BD. The results of these studies were discussed during OMERACT 2016 and next steps were planned.Results.Patients’ perspectives and priorities were identified through qualitative interviews that identified candidate domains and subdomains for inclusion in the Delphi and characterized some shortcomings of the currently used patient-reported outcomes in BD. The first round of the Delphi was completed and several domains or subdomains were endorsed by the experts and/or the patients. Because many more items were endorsed than would be feasible to assess during a clinical trial, rating and ranking of items by physicians and patients was planned as a next critical step. The challenges of assessing specific organ system involvement was also discussed.Conclusion.The OMERACT Behçet Syndrome Working Group research program will identify core domains for assessment in BD with the goal of developing a core set of outcome measures for use in all trials of BD with the option to incorporate additional outcomes for specific organ involvement.

Download Full-text